Natural Peptide Counters Multiple Hallmarks of Alzheimer’s

 Can your doctor rub a couple of neurons together and get human testing going? Or is sitting with heads up the ass the likely outcome?

Natural Peptide Counters Multiple Hallmarks of Alzheimer’s

Summary:

Researchers at UC San Diego have identified catestatin (CST), a naturally occurring peptide fragment, that simultaneously reduces amyloid and tau buildup, quells neuroinflammation, and improves cognitive and motor performance in mouse models of neurodegenerative disease. Unlike single-target therapies, CST acts across several interconnected pathological pathways, pointing toward a versatile peptide-based treatment strategy for complex dementias.

Key Facts:

• Multi-Target Clearance: In preclinical mouse models, treatment with catestatin significantly reduced toxic accumulations of both tau and amyloid proteins while dialing down neuroinflammation.
• Functional Recovery: Beyond clearing hallmark neuropathology, the peptide led to measurable improvements in both cognitive performance and motor coordination in animal models.
• Derived from Chromogranin A: CST is an endogenous cleavage product of chromogranin A, a protein fundamental to neurotransmitter storage and cellular signaling, and is currently being explored for its ability to reprogram brain energy metabolism to shield vulnerable neurons against cellular stress.

Source: University of California San Diego School of Medicine

Alzheimer’s disease and related dementias present one of the most stubborn hurdles in modern neurology, primarily because their pathology is not driven by a single isolated defect. Instead, disease progression involves an entangled network of problems: aberrant protein aggregation, persistent neuroinflammation, metabolic dysfunction, and progressive synaptic failure.

While many experimental drugs focus narrowly on single targets, such as clearing amyloid plaques or blocking tau tangles, a research team at the University of California San Diego School of Medicine and the VA San Diego Healthcare System took a different approach. In a study published in Molecular Therapy, the scientists investigated whether an endogenous peptide could intervene across multiple disease mechanisms simultaneously.

Their focus fell on catestatin (CST), a naturally occurring peptide fragment derived from chromogranin A. In animal models, CST not only cleared pathological hallmarks but also protected functional neural circuits.

“Neurodegenerative diseases involve multiple interconnected problems — including misfolded proteins, neuroinflammation and progressive dysfunction of brain cells,” said senior author Sushil K. Mahata, PhD, professor of medicine at UC San Diego School of Medicine and research physiologist at the VA San Diego Healthcare System.

“Our findings show that CST can act across several of these disease-associated pathways and shift the brain toward a healthier state. More broadly, the study suggests that peptide-based therapies may offer a new approach to treating complex neurodegenerative diseases.”

Reducing Amyloid, Tau, and Neuroinflammation

To evaluate the peptide’s therapeutic potential, the investigators administered CST to mouse models displaying hallmark features of neurodegenerative decline. The treatment produced widespread structural and cellular benefits:

• Toxin Clearance: CST significantly blunted the accumulation of both amyloid and tau aggregates, the twin proteinopathies characteristic of Alzheimer’s disease.
• Anti-Inflammatory Modulation: The peptide suppressed chronic neuroinflammatory signaling, reducing destructive immune activation in brain tissue.
• Behavioral and Motor Gains: Mice receiving CST demonstrated meaningful improvements in memory, learning tasks, and motor performance compared to untreated controls.

Because chromogranin A is naturally involved in cellular communication and the packaging and release of hormones and neurotransmitters, its derivative CST already plays diverse roles across cardiovascular, metabolic, and immune regulation throughout the body. This native systemic versatility appears to translate to the central nervous system, where it orchestrates several defensive processes rather than engaging only one receptor.

Cellular Resilience and Metabolic Support

Beyond cleaning up cellular debris and cooling inflammatory fires, the researchers are examining how CST alters neuronal bioenergetics.

“One exciting aspect of our findings is that CST may do more than reduce the pathological features of neurodegeneration. We are also investigating whether CST can alter how the brain produces and uses energy, which may help neurons become more resilient to the cellular stress that occurs during neurodegeneration,” said lead author Suborno Jati, PhD, a postdoctoral scholar at UC San Diego School of Medicine.

By potentially stabilizing how distressed brain cells generate and utilize ATP, CST could give damaged neurons the energetic bandwidth required to maintain synaptic communication despite accumulating toxic stressors.

The Path Forward

The researchers emphasize that the current findings are strictly preclinical. Moving CST or related peptide analogues from laboratory animal models into human clinical trials will require comprehensive studies to determine long-term safety, optimal dosing regimens, blood-brain barrier delivery dynamics, and clinical efficacy.

Nevertheless, the discovery highlights the promise of peptide therapeutics as multi-system regulators capable of treating the multifaceted biology of neurodegenerative decline.

Funding: The research was supported in part by grants from the National Institutes of Health and the U.S. Department of Veterans Affairs.

Mahata is founder of CgA Therapeuticals, Inc. and co-founder of Siraj Therapeutics. Mahata and Jati are listed as co-inventors on intellectual property related to the findings.

Editorial Notes:

• This article was edited by a Neuroscience News editor.
• Journal paper reviewed in full.
• Additional context added by our staff.

About this Genetics and Neuroregeneration Research:

• Media Contact: Miles Martin
• Source: UCSD
• Image Credit: Image credited to Neuroscience News
• Original Research is Open Access: Molecular Therapy (September 21, 2026). “Catestatin peptide ameliorates tauopathy and amyloidogenesis via adrenergic inhibition.” Authors: Suborno Jati, Satadeepa Kal, Daniel Munoz-Mayorga, Kechun Tang, Debashis Sahoo, Xu Chen, and Sushil K. Mahata.
• DOI: 10.1016/j.ymthe.2026.09.022